Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
The most recent articles from:
J Thorac Oncol
-
Editorial Comment
Pick the winner designs in phase II cancer clinical trials.
-
Randomized Controlled Trial Multicenter Study
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Gemcitabine and carboplatin combination therapy is an active and tolerable regimen in the treatment of non-small-cell lung cancer (NSCLC). Twenty-eight- and 21-day regimens without day-15 administration of gemcitabine are common; however, it remains unclear which offers the optimal therapeutic index. ⋯ Gemcitabine plus carboplatin is active and well tolerated in advanced NSCLC. Both regimens may be considered for further study. Although the 21-day regimen appeared to be associated with preferable outcomes, differences between treatment groups were not statistically significant.